查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1925539

第三方醫療檢測服務市場（按檢測類型、技術、檢體類型、最終用戶和應用分類）—2026-2032年全球預測

Third-party Medical Testing Services Market by Test Type, Technology, Sample Type, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，第三方醫療檢測服務市場規模將達到 39.4 億美元，到 2026 年將成長至 43 億美元，到 2032 年將達到 78.4 億美元，複合年成長率為 10.31%。

關鍵市場統計數據
基準年 2025 39.4億美元
預計年份：2026年 43億美元
預測年份 2032 78.4億美元
複合年成長率 (%) 10.31%

針對不斷變化的第三方醫療檢測環境，制定策略方法，明確臨床檢查室的促進因素、營運要務和產能優先事項。

本執行摘要概述了第三方醫療檢測服務的現狀，並闡述了構成該行業的核心結構因素和相關人員的期望。臨床檢查室、診斷中心和醫院網路在一個不斷變化的生態系統中運營，其特點是檢測項目日益複雜、對檢測結果的速度和準確性要求不斷提高，以及報銷機制和監管壓力不斷演變。在此背景下，具備營運靈活性和深厚技術實力的服務提供者更有能力在控制成本的同時滿足臨床醫生和患者的需求。

技術創新、不斷變化的法規和供應鏈韌性將如何共同重新定義診斷檢測服務的競爭優勢和價值創造

外包診斷檢測市場正受到變革性力量的重塑，而這些力量遠不止於簡單的技術替代。分子診斷技術的快速發展，特別是定序和聚合酵素鏈鎖反應）技術的臨床應用不斷擴展，使得疾病檢測更加精準，治療方案也更加個人化。同時，自動化和數位化檢查室解決方案正在簡化檢體處理和資料流，減少人工操作造成的誤差，並加快檢測速度。這些技術進步正推動檢測產業向高價值的專業檢測轉型，同時也拓展了第三方可進行的檢測範圍。

為因應2025年美國關稅調整，營運和採購的調整日益重視供應鏈韌性和成本透明度。

美國2025年實施的關稅和貿易政策趨勢為診斷檢測供應鏈帶來了新的成本和物流方面的挑戰。進口關稅及相關合規要求大幅提高了關鍵檢測設備、試劑和耗材的到岸成本。這迫使採購和營運團隊重新評估其籌資策略和庫存管理實務。為此，檢查室負責人正在審查供應商契約，盡可能探索本地生產，並調整庫存緩衝，以降低供應中斷和交付不確定性的風險。

將檢測類型、技術、最終用戶、應用和檢體類型與檢查室運營和能力優先事項聯繫起來的綜合細分觀點

對細分市場的深入理解揭示了技術能力與臨床需求和營運模式相符的領域。按檢測類型分類，臨床化學（細分為自動化化學分析儀和照護現場化學檢測）以及血液學、組織病理學、免疫學、微生物學和分子診斷（分子診斷又細分為次世代定序和PCR）均得到服務。這種多樣性決定了對資金和專業知識的不同需求：自動化化學平台優先考慮通量和可重複性，而分子檢測則需要嚴格的污染控制和生物資訊能力。

美洲、歐洲、中東和非洲以及亞太地區的區域戰略差異和營運重點會影響服務模式和夥伴關係關係策略。

區域趨勢正在影響美洲、歐洲、中東和非洲以及亞太地區的需求模式和營運策略。在美洲，醫療系統優先考慮整合、規模化和快速採用高通量平台，而公立和私立支付方則繼續透過報銷政策和合約實踐影響醫療服務利用趨勢。這種環境有利於那些能夠大規模提供穩定高品質服務並能與電子健康記錄和國家衛生數據基礎設施實現互通性的醫療服務提供者。

競爭格局洞察：揭示設備製造商、專業診斷公司和偵測網路如何利用合作關係和創新來實現差異化競爭

競爭動態由成熟的儀器製造商、專業的分子診斷公司、大型檢測服務供應商以及新興的平台創新者共同塑造。供應商不斷透過整合硬體、試劑和軟體支援的解決方案來推動市場應用，使檢查室能夠提高檢測通量、增強結果的可重複性並簡化維護。同時，專業的分子診斷和定序公司正透過將產品與精簡的工作流程結合，拓展其在臨床市場的業務，從而提供臨床檢驗證據並加快結果出爐速度。

為診斷領導者提供切實可行的優先行動方案，以增強平台柔軟性、供應商韌性、證據產生、員工能力和數位化整合。

產業領導者應採取務實且優先的行動方案，使產能投資與不斷變化的臨床需求和營運韌性保持一致。首先，選擇性地投資於模組化、可互通的平台，這些平台既支援高通量自動化化學檢測，也支援先進的分子工作流程，從而能夠靈活適應不斷變化的檢測組合。其次，加強供應商多元化和最佳化合約條款，以降低關稅帶來的供應風險，同時促進短期供應的連續性和長期成本的透明度。

調查方法透明度：說明如何將一手訪談、實地觀察、二手資料和專家檢驗結合，從而得出可操作的檢查室。

本研究結合了一手和二手研究方法，以確保研究結果得到穩健且多層次的檢驗。一手研究包括對實驗室主任、採購人員、臨床相關人員和技術供應商進行結構化訪談，以及實地考察和工作流程觀察，以實際操作資料佐證定性研究結果。二手研究涵蓋行業文獻、監管指導文件、技術白皮書和製造商規格說明，以闡明技術能力和合規要求。

將技術準備、供應鏈策略、監管合規性和夥伴關係模式與永續競爭優勢連結起來的綜合結論

分析結果表明，第三方醫療檢測服務正處於一個轉折點，技術能力、合規性和供應鏈韌性將共同決定其競爭優勢。專注於投資互通平台並建立多元化供應商關係的機構，將更有能力提供一致的臨床質量，同時克服貿易相關的成本和物流壓力。同時，未能將證據生成與臨床效用相結合的機構，則可能面臨推廣速度放緩和支付方支持不足的風險。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 第三方醫療檢測服務市場（依檢測類型分類）

  • 臨床化學
    • 自動化學分析儀
    • 照護現場化學檢測
  • 血液學
  • 組織病理學
  • 免疫學
  • 微生物學
  • 分子診斷
    • 次世代定序
    • PCR

9. 按技術分類的第三方醫療檢測服務市場

  • 免疫檢測
  • 質譜分析
  • 顯微鏡
  • PCR
    • 數位PCR
    • 定量PCR
  • 定序

第10章：依檢體類型分類的第三方醫療檢測服務市場

  • 血
    • 電漿
    • 血清
    • 全血
  • 唾液
  • 組織
  • 尿

第11章 以最終用戶分類的第三方醫療檢測服務市場

  • 學術研究機構
  • 診斷中心
  • 醫院
    • 私立醫院
    • 公立醫院
  • 製藥和生物技術公司

第12章 第三方醫療檢測服務市場（按應用領域分類）

  • 心臟病學
  • 基因檢測
  • 感染疾病
  • 神經病學
  • 腫瘤學
    • 液態生物檢體
    • 組織切片檢查

第13章 第三方醫療檢測服務市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 第三方醫療檢測服務市場（以群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國第三方醫療檢測服務市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國第三方醫療檢測服務市場

第17章：中國第三方醫療檢測服務市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ARUP Laboratories LLC
  • Bio-Reference Laboratories Inc
  • Cerba Healthcare SA
  • Cerberus Diagnostics Inc
  • Charles River Laboratories International Inc
  • Element Materials Technology Ltd
  • Eurofins Scientific SE
  • Fulgent Genetics Inc
  • ICON plc
  • Intertek Group plc
  • IQVIA Holdings Inc
  • Labcorp Holdings Inc
  • Mayo Foundation for Medical Education and Research
  • Medpace Holdings Inc
  • NeoGenomics Laboratories Inc
  • OPKO Health Inc
  • PPD Inc
  • Quest Diagnostics Incorporated
  • SGS SA
  • Sonic Healthcare Limited
  • SYNLAB AG
  • TUV SUD AG
  • Unilabs Holding SA
  • WuXi AppTec Co Ltd
Product Code: MRR-7A380DA7C6A2

The Third-party Medical Testing Services Market was valued at USD 3.94 billion in 2025 and is projected to grow to USD 4.30 billion in 2026, with a CAGR of 10.31%, reaching USD 7.84 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.94 billion
Estimated Year [2026] USD 4.30 billion
Forecast Year [2032] USD 7.84 billion
CAGR (%) 10.31%

A strategic orientation to the evolving third-party medical testing landscape that clarifies drivers, operational imperatives, and capability priorities for clinical laboratories

This executive summary frames the contemporary landscape for third-party medical testing services, outlining the core structural forces and stakeholder expectations that define the sector. Clinical laboratories, diagnostic centers, and hospital networks are operating within a shifting ecosystem characterized by rising complexity in test portfolios, a heightened emphasis on turn-around time and accuracy, and evolving reimbursement and regulatory pressures. In this context, providers that combine operational agility with deep technical capability are better positioned to meet clinician and patient needs while controlling costs.

The industry is also undergoing a technology-led reconfiguration where advanced molecular platforms, automation in clinical chemistry, and integrated information systems play an increasingly central role. These technological shifts are influencing how samples are processed, how results are reported, and how laboratories collaborate with pharmaceutical companies and academic research institutions. At the same time, changing patterns in care delivery, including outpatient diagnostics and decentralized testing models, are redefining the interplay between centralized reference labs and point-of-care services. Consequently, executives must reconcile legacy laboratory processes with the imperative to adopt flexible, interoperable platforms that support new test modalities and data-driven decision-making.

Taken together, these dynamics demand strategic clarity around capability investments, partnerships, and talent models. The remainder of this summary unpacks the transformative shifts, tariff implications, segmentation insights, regional differentiators, competitive movements, and practical recommendations that will guide effective decision-making in the near term.

How technological advances, regulatory evolution, and supply chain resilience are jointly redefining competitive advantage and value creation in diagnostic testing services

The marketplace for outsourced diagnostic testing is being reshaped by a constellation of transformative forces that extend beyond simple technological substitution. Rapid advances in molecular diagnostics, particularly the broader clinical application of sequencing and polymerase chain reaction techniques, are enabling more precise disease detection and personalized therapy selection. Concurrently, automation and digital laboratory solutions are streamlining sample handling and data flows, which reduces manual variability and accelerates result delivery. These technical developments are reinforcing a shift toward higher-value, specialized testing while expanding the scope of tests that can be feasibly offered by third-party providers.

In parallel, regulatory rigor and quality expectations have intensified, prompting laboratories to invest in standardized procedures, robust quality controls, and accreditation pathways. Payer behavior and clinical guideline evolution are exerting pressure on test utilization patterns, encouraging clearer clinical validation and outcome linkage. Moreover, supply chain resilience has become an operational priority, with procurement teams diversifying sources and building redundancy for critical reagents and instrumentation. As a result, strategic partnerships, vendor consolidation, and targeted alliances between diagnostic companies and clinical laboratories have become commonplace.

Finally, patient-centric care models and health system consolidation are altering referral flows and demand geography. Decentralized testing and point-of-care modalities are growing alongside centralized reference services, creating hybrid service models. The cumulative effect is a marketplace where technical excellence, quality governance, and strategic connectivity determine competitive positioning and long-term viability.

Operational and procurement adaptations driven by 2025 United States tariff adjustments that have increased emphasis on supply chain resilience and cost transparency

Tariff and trade policy developments in the United States for 2025 introduced new cost and logistics considerations that reverberate across the diagnostic testing supply chain. Import duties and related compliance requirements have increased the effective landed cost of critical laboratory equipment, reagents, and consumables, which in turn has forced procurement and operations teams to reassess sourcing strategies and inventory approaches. In response, laboratory leaders have revisited supplier contracts, sought local manufacturing where feasible, and adjusted inventory buffers to mitigate disruption risk and delivery lead time uncertainty.

Beyond procurement, the tariff landscape has sharpened focus on total cost of ownership, prompting organizations to evaluate equipment interoperability, maintenance contracts, and consumable dependencies more closely. Longer-term service agreements and multi-supplier sourcing arrangements have become pragmatic responses to avoid overreliance on single vendors whose components may be subject to fluctuating trade barriers. Regulatory compliance and customs classification accuracy have also risen in priority to avoid unexpected tariff application or clearance delays that can affect testing continuity.

Operational teams have responded with workflow and scheduling adaptations to smooth throughput during periods of constrained supply. Partnerships with regional suppliers and investment in platform-agnostic assays have reduced exposure to trade-related volatility. Overall, the tariff environment has accelerated strategic behaviors that emphasize resilience, contractual flexibility, and closer alignment between procurement, quality, and clinical operations.

Integrated segmentation perspectives linking test types, technologies, end users, applications, and sample types to operational and capability priorities for laboratories

A nuanced understanding of segmentation reveals where technical capacity aligns with clinical demand and operational models. By test type, services encompass Clinical Chemistry-further delineated into Automated Chemistry Analyzers and Point of Care Chemistry Testing-alongside Hematology, Histopathology, Immunology, Microbiology, and Molecular Diagnostics, with Molecular Diagnostics further characterized by Next Generation Sequencing and PCR. This diversity creates differentiated capital and expertise requirements, with automated chemistry platforms prioritizing throughput and reproducibility, and molecular modalities demanding stringent contamination control and bioinformatics capability.

When considering end users, the landscape includes Academic And Research Institutes, Diagnostic Centers, Hospitals, and Pharmaceutical And Biotech Companies, where Hospitals are further categorized into Private Hospitals and Public Hospitals. Each end user type brings distinct service expectations: academic and research institutions often require specialized assays and data sharing for studies, diagnostic centers value rapid turnarounds and scalable workflows, hospitals prioritize integration with clinical systems and on-site logistics, and industry customers demand analytical rigor and compliance for clinical trials and companion diagnostics.

Technology segmentation spans Immunoassays, Mass Spectrometry, Microscopy, PCR, and Sequencing, with PCR further broken down into Digital PCR and Quantitative PCR. Application areas include Cardiology, Genetic Testing, Infectious Diseases, Neurology, and Oncology, where Oncology itself is delineated into Liquid Biopsy and Tissue Biopsy. Sample types range across Blood, Saliva, Tissue, and Urine, with Blood further divided into Plasma, Serum, and Whole Blood. These intersecting vectors inform decisions about laboratory layout, staffing, quality systems, and informatics, and they guide which value propositions resonate with varied clinical and commercial stakeholders.

Regional strategic contrasts and operational priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence service models and partnership strategies

Regional dynamics shape both demand patterns and operational strategy across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, health systems emphasize consolidation, scale, and rapid adoption of high-throughput platforms, and private and public payers continue to influence utilization through reimbursement policy and contracting practices. This environment favors providers that can deliver consistent quality at scale and that demonstrate interoperability with electronic health records and national health data infrastructure.

Across Europe, Middle East & Africa, regulatory complexity and heterogeneous payer landscapes create differentiated entry and operational models. Laboratories and service providers in this region must navigate diverse accreditation standards, cross-border logistics, and variable clinical guideline adoption while capitalizing on pockets of innovation in molecular diagnostics and centralized testing collaborations. The region often requires tailored service and compliance approaches that reflect local clinical pathways and procurement norms.

In Asia-Pacific, rapid investment in healthcare infrastructure, coupled with a strong focus on precision medicine initiatives in several markets, is driving demand for both centralized reference testing and decentralized modalities. Procurement strategies tend to balance cost sensitivity with a willingness to adopt novel technologies that demonstrate clear clinical utility. Across all regions, cross-border partnerships, regional manufacturing, and adaptive regulatory strategies are important mechanisms by which providers manage complexity and optimize service delivery.

Competitive landscape insights showing how instrument providers, specialty diagnostics firms, and laboratory networks are leveraging partnerships and innovation to differentiate

Competitive dynamics are shaped by a mix of established instrument manufacturers, specialized molecular diagnostics firms, large laboratory service providers, and emerging platform innovators. Instrument vendors continue to drive adoption through integrated solutions that combine hardware, reagents, and software support, enabling laboratories to upgrade throughput and enhance reproducibility while simplifying maintenance. At the same time, specialist molecular and sequencing companies are expanding into clinical markets by aligning their offerings with clinical validation evidence and streamlined workflows that reduce time to result.

Large laboratory service providers maintain competitive advantage through scale, logistics networks, and integration into clinical care pathways, often leveraging their size to secure favorable supplier terms and to invest in automation. Meanwhile, start-ups and technology-focused newcomers push innovation in areas such as digital PCR, liquid biopsy analytics, and lab automation, forcing incumbents to accelerate modernization. Partnerships and horizontal integrations have become common approaches to broaden test menus and to enter new geographic markets without the full capital outlay of greenfield facilities.

Strategic differentiation increasingly rests on the ability to combine technical excellence with commercialization capabilities, including clinician engagement, payer alignment, and evidence generation. Companies that can demonstrate clinical utility, streamline onboarding for health systems, and provide robust customer support are more successful in securing long-term contracts and collaborative research partnerships.

Practical, prioritized actions for diagnostic leaders to enhance platform flexibility, supplier resilience, evidence generation, workforce capability, and digital integration

Industry leaders should adopt a set of pragmatic, prioritized actions that align capability investment with evolving clinical demand and operational resilience. First, invest selectively in modular, interoperable platforms that support both high-throughput automated chemistry and advanced molecular workflows, thereby preserving flexibility as test mixes shift. Second, strengthen supplier diversification and contractual terms to mitigate tariff-induced supply risks while promoting near-term continuity and long-term cost transparency.

Third, align commercial and clinical strategies by building stronger evidence-generation capabilities that link diagnostic results to actionable clinical outcomes, which supports payer negotiations and clinician adoption. Fourth, deploy workforce development programs focused on molecular techniques, bioinformatics, and laboratory automation to bridge skills gaps. Fifth, pursue targeted regional strategies that reflect local regulatory, reimbursement, and clinical practice differences, leveraging partnerships with regional players where appropriate to accelerate market entry.

Finally, accelerate digital integration across laboratory information systems, result reporting, and clinician-facing platforms to improve throughput, reduce errors, and support data-driven service design. Executing these recommendations will require coordinated governance, clear prioritization of capital allocation, and continuous monitoring of regulatory and trade developments to adapt quickly as circumstances evolve.

Methodological transparency describing how primary interviews, site observations, secondary sources, and expert validation were combined to produce actionable laboratory insights

This research synthesized primary and secondary methods to ensure robust, multilevel validation of insights. Primary research included structured interviews with laboratory directors, procurement leads, clinical stakeholders, and technology vendors, combined with site visits and workflow observations to ground qualitative findings in operational reality. Secondary research encompassed industry literature, regulatory guidance documents, technical white papers, and manufacturer specifications to contextualize technology capabilities and compliance requirements.

Data triangulation was achieved by cross-referencing interview inputs with publicly available regulatory filings, corporate disclosures, and technical specifications to identify consistent patterns and to reconcile divergent viewpoints. Quality assurance included peer review of methodology and findings by domain experts in laboratory operations, molecular diagnostics, and healthcare economics. Segmentation mapping aligned test types, technologies, applications, sample types, and end-user characteristics to ensure that analyses reflected the practical intersections that determine service design and capability needs.

Limitations and mitigations are transparently documented, including the dynamic nature of regulatory environments and trade policies, which the methodology addressed by incorporating the most current guidance and by validating operational implications through multiple stakeholder perspectives. This approach produced actionable intelligence that balances rigor with practical relevance for industry decision-makers.

Concluding synthesis that ties technological readiness, supply chain strategies, regulatory navigation, and partnership models to sustainable competitive positioning

This body of analysis concludes that third-party medical testing services are at an inflection point where technological capability, regulatory compliance, and supply chain resilience collectively determine competitive advantage. Providers that invest in interoperable platforms and cultivate diversified supplier relationships will be better equipped to navigate trade-related cost and logistics pressures while delivering consistent clinical quality. At the same time, those that fail to align evidence generation with clinical utility risk slower adoption and constrained payer support.

Moreover, regional nuances demand tailored approaches that respect local regulatory frameworks, reimbursement models, and clinical practice patterns. Strategic partnerships, whether for regional distribution, co-development, or shared laboratory capacity, offer a pragmatic pathway to expansion without undue capital strain. Workforce capability and digital integration are persistent enablers; investments in these areas yield improvements in throughput, error reduction, and clinician satisfaction.

In sum, successful organizations will combine technical excellence with operational discipline, strategic supplier management, and clinician-focused commercialization to capture durable value. The recommendations outlined provide a roadmap for executives to prioritize investments and to structure cross-functional initiatives that translate insights into measurable operational improvements and stronger clinical partnerships.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Third-party Medical Testing Services Market, by Test Type

  • 8.1. Clinical Chemistry
    • 8.1.1. Automated Chemistry Analyzers
    • 8.1.2. Point Of Care Chemistry Testing
  • 8.2. Hematology
  • 8.3. Histopathology
  • 8.4. Immunology
  • 8.5. Microbiology
  • 8.6. Molecular Diagnostics
    • 8.6.1. Next Generation Sequencing
    • 8.6.2. PCR

9. Third-party Medical Testing Services Market, by Technology

  • 9.1. Immunoassays
  • 9.2. Mass Spectrometry
  • 9.3. Microscopy
  • 9.4. PCR
    • 9.4.1. Digital PCR
    • 9.4.2. Quantitative PCR
  • 9.5. Sequencing

10. Third-party Medical Testing Services Market, by Sample Type

  • 10.1. Blood
    • 10.1.1. Plasma
    • 10.1.2. Serum
    • 10.1.3. Whole Blood
  • 10.2. Saliva
  • 10.3. Tissue
  • 10.4. Urine

11. Third-party Medical Testing Services Market, by End User

  • 11.1. Academic And Research Institutes
  • 11.2. Diagnostic Centers
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals
  • 11.4. Pharmaceutical And Biotech Companies

12. Third-party Medical Testing Services Market, by Application

  • 12.1. Cardiology
  • 12.2. Genetic Testing
  • 12.3. Infectious Diseases
  • 12.4. Neurology
  • 12.5. Oncology
    • 12.5.1. Liquid Biopsy
    • 12.5.2. Tissue Biopsy

13. Third-party Medical Testing Services Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Third-party Medical Testing Services Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Third-party Medical Testing Services Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Third-party Medical Testing Services Market

17. China Third-party Medical Testing Services Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. ARUP Laboratories LLC
  • 18.6. Bio-Reference Laboratories Inc
  • 18.7. Cerba Healthcare SA
  • 18.8. Cerberus Diagnostics Inc
  • 18.9. Charles River Laboratories International Inc
  • 18.10. Element Materials Technology Ltd
  • 18.11. Eurofins Scientific SE
  • 18.12. Fulgent Genetics Inc
  • 18.13. ICON plc
  • 18.14. Intertek Group plc
  • 18.15. IQVIA Holdings Inc
  • 18.16. Labcorp Holdings Inc
  • 18.17. Mayo Foundation for Medical Education and Research
  • 18.18. Medpace Holdings Inc
  • 18.19. NeoGenomics Laboratories Inc
  • 18.20. OPKO Health Inc
  • 18.21. PPD Inc
  • 18.22. Quest Diagnostics Incorporated
  • 18.23. SGS SA
  • 18.24. Sonic Healthcare Limited
  • 18.25. SYNLAB AG
  • 18.26. TUV SUD AG
  • 18.27. Unilabs Holding SA
  • 18.28. WuXi AppTec Co Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY AUTOMATED CHEMISTRY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY AUTOMATED CHEMISTRY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY AUTOMATED CHEMISTRY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY POINT OF CARE CHEMISTRY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY POINT OF CARE CHEMISTRY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY POINT OF CARE CHEMISTRY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HEMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HEMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 240. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 242. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. GCC THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 273. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 274. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY PCR, 2018-2032 (USD MILLION)
  • TABLE 276. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 278. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 280. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. G7 THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. NATO THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. NATO THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. NATO THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY CLINICAL CHEMISTRY, 2018-2032 (USD MILLION)
  • TABLE 285. NATO THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 286. NATO THIRD-PARTY MEDICAL TESTING SERVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. NATO THIRD-PARTY MEDICAL TESTING SERVICES MARKET